Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations

Vince Russell, Andrew Connolly, Joanna Dlugozima, Paul Woodman, Alan Young
European Respiratory Journal 2013 42: P672; DOI:
Vince Russell
1Pharmacology, Argenta, Stoke Poges, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Connolly
1Pharmacology, Argenta, Stoke Poges, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Dlugozima
1Pharmacology, Argenta, Stoke Poges, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Woodman
1Pharmacology, Argenta, Stoke Poges, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Young
1Pharmacology, Argenta, Stoke Poges, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Exposure to tobacco smoke (TS) for 4d induced a steroid-insensitive lung inflammation in mice which was exaggerated by the addition of the viral mimetic poly IC (pIC). The effects of an inhaled steroid and an inhaled p38 inhibitor on the exaggerated inflammation were examined.

Methods Mice were exposed to air or TS for 4d. Saline or pIC was administered intra-nasally and mice killed 24h after the last exposure, the lungs lavaged and cells counted. Single intra-nasal doses of vehicle, Fluticasone proprionate (FP, 0.3mg/kg) or the p38 inhibitor PF-03715455 (PF-55, 0.1mg/kg) were dosed 2h after the final challenge.

Results TS-exposure caused a significant cellular infiltration into the lung, which was not inhibited by single doses of either PF-55 or FP. In non-TS exposed mice, pIC induced an inflammation which was also not inhibited by either PF-55 or FP. Administration of pIC in addition to TS-exposure induced an exaggerated inflammatory response which was greater than the additive effect of the two stimuli, with large increases in neutrophil numbers in particular (TS ∼0.07 million, PIC ∼0.2 million, TS+PIC ∼0.6 million). The inflammation at 24h after exposure was significantly inhibited by both PF-55 (54%, p<0.0001) and FP (44%, p<0.001), in contrast to the lack of efficacy of either compound in the TS or PIC groups. However, the level of inflammation never fell below the TS-alone baseline.

Conclusions TS exposure for 4d induced a lung inflammation which was insensitive to steroid. Addition of PIC elicited a markedly enhanced inflammatory response that was sensitive to intra-nasal administration of PF-03715455 and also to FP, thus mimicking features of human COPD.

  • Animal models
  • Anti-inflammatory
  • Pharmacology
  • © 2013 ERS
Previous
Back to top
Vol 42 Issue Suppl 57 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
Vince Russell, Andrew Connolly, Joanna Dlugozima, Paul Woodman, Alan Young
European Respiratory Journal Sep 2013, 42 (Suppl 57) P672;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
Vince Russell, Andrew Connolly, Joanna Dlugozima, Paul Woodman, Alan Young
European Respiratory Journal Sep 2013, 42 (Suppl 57) P672;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Direct activation of sensory afferents by diesel exhaust particles can trigger respiratory symptoms
  • Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model
  • Dysphonia in asthmatic women using inhaled corticosteroids: It is not only a laryngeal inflammation
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society